Prevention and Treatment of Bone Metastases in Breast Cancer

被引:9
作者
Ripamonti, Carla [1 ]
Trippa, Fabio [2 ]
Barone, Gloria [1 ]
Maranzano, Ernesto [2 ]
机构
[1] Fdn IRCCS, Ist Nazl Tumori Milano, Dept Haematol & Pediat Oncohaematol, Support Care Canc Unit, I-20133 Milan, Italy
[2] Hosp Santa Maria, Radiat Oncol Ctr, Oncol Dept, Via T di Joannuccio, I-05100 Terni, Italy
关键词
breast cancer; bone metastases; radiotherapy; bisphosphonates; endocrine therapy; chemotherapy; bone pain relief;
D O I
10.3390/jcm2030151
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In breast cancer patients, bone is the most common site of metastases. Medical therapies are the basic therapy to prevent distant metastases and recurrence and to cure them. Radiotherapy has a primary role in pain relief, recalcification and stabilization of the bone, as well as the reduction of the risk of complications (e.g., bone fractures, spinal cord compression). Bisphosphonates, as potent inhibitors of osteoclastic-mediated bone resorption are a well-established, standard-of-care treatment option to reduce the frequency, severity and time of onset of the skeletal related events in breast cancer patients with bone metastases. Moreover bisphosphonates prevent cancer treatment-induced bone loss. Recent data shows the anti-tumor activity of bisphosphonates, in particular, in postmenopausal women and in older premenopausal women with hormone-sensitive disease treated with ovarian suppression. Pain is the most frequent symptom reported in patients with bone metastases, and its prevention and treatment must be considered at any stage of the disease. The prevention and treatment of bone metastases in breast cancer must consider an integrated multidisciplinary approach.
引用
收藏
页码:151 / 175
页数:25
相关论文
共 103 条
[2]  
Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0
[3]   Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials [J].
Albain, K. ;
Anderson, S. ;
Arriagada, R. ;
Barlow, W. ;
Bergh, J. ;
Bliss, J. ;
Buyse, M. ;
Cameron, D. ;
Carrasco, E. ;
Clarke, M. ;
Correa, C. ;
Coates, A. ;
Collins, R. ;
Costantino, J. ;
Cutter, D. ;
Cuzick, J. ;
Darby, S. ;
Davidson, N. ;
Davies, C. ;
Davies, K. ;
Delmestri, A. ;
Di Leo, A. ;
Dowsett, M. ;
Elphinstone, P. ;
Evans, V. ;
Ewertz, M. ;
Gelber, R. ;
Gettins, L. ;
Geyer, C. ;
Goldhirsch, A. ;
Godwin, J. ;
Gray, R. ;
Gregory, C. ;
Hayes, D. ;
Hill, C. ;
Ingle, J. ;
Jakesz, R. ;
James, S. ;
Kaufmann, M. ;
Kerr, A. ;
MacKinnon, E. ;
McGale, P. ;
McHugh, T. ;
Norton, L. ;
Ohashi, Y. ;
Paik, S. ;
Pan, H. C. ;
Perez, E. ;
Peto, R. ;
Piccart, M. .
LANCET, 2012, 379 (9814) :432-444
[4]  
*AM ASS OR MAX SUR, POS PAP BISPH REL OS
[5]   Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial [J].
Amadori, Dino ;
Aglietta, Massimo ;
Alessi, Barbara ;
Gianni, Lorenzo ;
Ibrahim, Toni ;
Farina, Gabriella ;
Gaion, Fernando ;
Bertoldo, Francesco ;
Santini, Daniele ;
Rondena, Roberta ;
Bogani, Paola ;
Ripamonti, Carla I. .
LANCET ONCOLOGY, 2013, 14 (07) :663-670
[6]   PHASE I TRIAL OF VERTEBRAL INTRACAVITARY CEMENT AND SAMARIUM (VICS): NOVEL TECHNIQUE FOR TREATMENT OF PAINFUL VERTEBRAL METASTASIS [J].
Ashamalla, Hani ;
Cardoso, Erico ;
Macedon, Mark ;
Guirguis, Adel ;
Weng, Lijun ;
Ali, Shamsah ;
Mokhtar, Bahaa ;
Ashamalla, Michael ;
Panigrahi, Nokul .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03) :836-842
[7]   Surgical Intervention of Nonvertebral Osseous Metastasis [J].
Attar, Samer ;
Steffner, Robert J. ;
Avedian, Raffi ;
Hussain, Waqas M. .
CANCER CONTROL, 2012, 19 (02) :113-121
[8]   Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases [J].
Body, JJ ;
Diel, IJ ;
Lichinitser, MR ;
Kreuser, ED ;
Dornoff, W ;
Gorbunova, VA ;
Budde, M ;
Bergström, B .
ANNALS OF ONCOLOGY, 2003, 14 (09) :1399-1405
[9]  
BYRNE TN, 1992, NEW ENGL J MED, V327, P614
[10]  
Cai Beilei, 2013, J Pain Palliat Care Pharmacother, V27, P28, DOI 10.3109/15360288.2012.757267